SEC Comment Letter 0000000000-23-003512 to G1 Therapeutics, Inc. (GTHX) (CIK 0001560241)
G1 Therapeutics, Inc. (GTHX) (CIK 0001560241)
Date: April 7, 2023 · CIK: 0001560241 · Accession: 0000000000-23-003512
AI Filing Summary & Sentiment
File numbers found in text: 001-38096
Letter
United States securities and exchange commission logo April 7, 2023 John Umstead Chief Financial Officer G1 Therapeutics, Inc. 700 Park Offices Drive, Suite 200 Research Triangle Park, North Carolina 27709 Re:G1 Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 1, 2023 File No. 001-38096 Dear John Umstead: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to the comment, we may have additional comments. Form 10-K for the Fiscal Year Ended December 31, 2022 Exhibits Exhibit 23.1 Consent of PricewaterhouseCoopers LLP, page 112 1.Please amend your filing to include a signed consent from PricewaterhouseCoopers LLP.
FirstName LastName John Umstead Comapany NameG1 Therapeutics, Inc. April 7, 2023 Page 2 FirstName LastName John Umstead G1 Therapeutics, Inc. April 7, 2023 Page 2 In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Frank Wyman at 202-551-3660 or Mary Mast at 202-551-3613 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
April 7, 2023
John Umstead
Chief Financial Officer
G1 Therapeutics, Inc.
700 Park Offices Drive, Suite 200
Research Triangle Park, North Carolina 27709
Re:G1 Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 1, 2023
File No. 001-38096
Dear John Umstead:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment. In our comment, we may ask you to provide us
with information so we may better understand your disclosure.
Please respond to the comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to the comment, we may have additional comments.
Form 10-K for the Fiscal Year Ended December 31, 2022
Exhibits
Exhibit 23.1 Consent of PricewaterhouseCoopers LLP, page 112
1.Please amend your filing to include a signed consent from PricewaterhouseCoopers LLP.
FirstName LastName John Umstead
Comapany NameG1 Therapeutics, Inc.
April 7, 2023 Page 2
FirstName LastName
John Umstead
G1 Therapeutics, Inc.
April 7, 2023
Page 2
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
You may contact Frank Wyman at 202-551-3660 or Mary Mast at 202-551-3613 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences